Ras

Cat. No.

A63692

CAS No.

3030078-96-4

KRAS inhibitor-35

KRAS Inhibitor-35 (compound 72) is a potent inhibitor of KRAS with an IC50 of 2 nM. It effectively disrupts KRAS signaling pathways, making it a valuable tool for studying tumor biology and the role of KRAS mutations in cancer research. This compound is suitable for various in vitro and in vivo applications aimed at exploring therapeutic strategies targeting KRAS-driven malignancies.

Cat. No.

A63693

CAS No.

2660129-56-4

KRAS G12C inhibitor 38

KRAS G12C inhibitor 38 is a selective inhibitor targeting the mutant form of KRAS G12C, an essential component of intracellular signaling pathways involved in cellular growth and proliferation. This compound exhibits significant anti-cancer activity and is primarily applied in research focused on KRAS G12C-driven malignancies. Its utilization can aid in the exploration and understanding of therapeutic strategies against cancers characterized by KRAS mutations.

Cat. No.

A63694

CAS No.

3033236-98-2

KRAS G12C Ligand-Linker Conjugates 1

KRAS G12C Ligand-Linker Conjugates 1 is a conjugate formed from the KRAS G12C ligand and a linker moiety. This compound is designed to facilitate the targeted degradation of KRAS G12C proteins through the synthesis of PROTAC YF135. It serves as a valuable tool for studying KRAS-related signaling pathways and exploring therapeutic strategies in KRAS-driven cancers.

Cat. No.

A63695

CAS No.

2230873-66-0

KRAS inhibitor-18

KRAS inhibitor-18 is a selective inhibitor targeting the KRAS G12C mutation, demonstrating a potent inhibitory effect with an IC50 of 4.74 µM. This compound effectively inhibits phosphorylated ERK in MIA PaCA-2 and A549 cell lines, with IC50 values of 66.4 µM and 11.1 µM, respectively. KRAS inhibitor-18 is valuable for research applications in pancreatic, colorectal, and lung cancer studies, facilitating investigations into KRAS-driven tumorigenesis and potential therapeutic interventions.

Cat. No.

A63696

CAS No.

690696-36-7

SOS2 ligand 1

SOS2 Ligand 1 is a selective ligand that targets son of sevenless 2 (SOS2), exhibiting a KD value of 4.6 µM. This compound is valuable for studying the role of SOS2 in cellular signaling pathways and may facilitate research in cancer biology and related fields. Its specificity for SOS2 makes it a useful tool for investigating SOS2-mediated processes and potential therapeutic interventions.

Cat. No.

A63697

CAS No.

1092521-74-8

Farnesyl thiosalicylic acid amide

Synonyms: FTS amide; Salirasib amide

Farnesyl thiosalicylic acid amide (FTS-A) is an orally active derivative that targets the farnesyl thiosalicylic acid pathway. It effectively reduces Ras-GTP levels, demonstrating significant inhibition of cell growth in Panc-1 and U87 cell lines, with IC50 values of 20 μM and 10 μM, respectively. This compound is relevant for cancer research, offering potential insights into Ras signaling and therapeutic strategies.

Cat. No.

A63698

CAS No.

1009376-10-6

RTIL 13

RTIL 13 is a selective inhibitor of dynamin GTPase, demonstrating an IC50 value of 2.3 μM for dynamin I. Additionally, it interacts with the pleckstrin homology lipid-binding domain. RTIL 13 effectively inhibits receptor-mediated endocytosis and synaptic vesicle endocytosis, with IC50 values of 9.3 μM and 7.1 μM, respectively. This compound is valuable for research focused on vesicle trafficking and cellular uptake mechanisms.

Cat. No.

A63699

CAS No.

1351669-68-5

Palmostatin M

Palmostatin M is a Ras signaling modulator that specifically targets acyl-protein thioesterases 1 and 2 (APT1 and APT2), exhibiting an IC50 of 2.5 nM for APT1. By disrupting the depalmitoylation cycle of Ras, Palmostatin M effectively downregulates the Ras signaling pathway. This compound is particularly relevant for studies investigating cancer biology and the modulation of Ras-driven signaling networks.

Cat. No.

A63700

CAS No.

3033641-67-4

KRAS-IN-42

KRAS-IN-42 is a covalent inhibitor specifically targeting KRASG12D mutants. This compound exhibits potent activity against KRASG12D-driven cancers, including non-small cell lung cancer and colorectal cancer. It is a valuable tool for researchers studying the molecular mechanisms and therapeutic options for KRASG12D-mutant oncogenesis.

Cat. No.

A63701

CAS No.

2883034-05-5

KRAS G12D modulator-1

KRAS G12D modulator-1 is an effective modulator targeting the KRAS G12D mutation. It exhibits potent activity with IC50 values ranging from 1 to 10 μM against NEA-G12D, PPI-G12D, and phosphorylated ERK in AGS cells. This compound is suitable for research applications focused on cancer biology and the modulation of KRAS signaling pathways.

Cat. No.

A63702

CAS No.

2648808-69-7

KRAS G12C inhibitor 43

KRAS G12C inhibitor 43 is a selective inhibitor targeting the KRAS G12C mutation, a key driver in various cancers. It demonstrates significant anti-migration and anti-proliferative activities, with IC50 values ranging from 0.001 to 1 µM in H358, A549, and HCC cell lines. This compound holds potential for research applications focused on cancer progression and therapeutic development against KRAS-driven malignancies.

Cat. No.

A63703

CAS No.

3056974-50-3

KRAS-IN-41

KRAS-IN-41 is a potent inhibitor of the KRAS oncogene, exhibiting IC50 values of less than 0.01 μM against both KRAS G12D and KRAS G12V variants. This compound effectively inhibits the proliferation of RAS mutant cell lines, including GP2D and SW620, demonstrating its potential for therapeutic application. KRAS-IN-41 is suitable for use in cancer research, particularly in studies focused on targeting KRAS mutations.

Cat. No.

A63705

CAS No.

2760354-12-7

KRAS G12C inhibitor 50

KRAS G12C Inhibitor 50 is a potent small molecule that selectively targets the KRAS G12C mutant protein, exhibiting an IC50 of 46.7 nM. This compound is instrumental in cancer research, particularly in studies focused on KRAS-driven tumors. Its ability to inhibit KRAS G12C activity makes it a valuable tool for investigating therapeutic strategies and potential treatments for malignancies associated with this mutation.

Cat. No.

A63706

CAS No.

3079342-05-2

KRAS-IN-47

KRAS-IN-47 is a potent inhibitor of the KRAS protein, specifically targeting the KRAS G12V mutant with an IC50 of less than 50 nM. This compound is valuable for research applications focused on understanding KRAS-driven cancers, providing insights into tumor biology and therapeutic resistance mechanisms. The inhibitor's efficacy in modulating KRAS activity makes it a critical tool for studying the role of this oncogene in cancer progression and treatment response.

Cat. No.

A63707

CAS No.

2923669-28-5

KRAS G12D inhibitor 28

KRAS G12D inhibitor 28 selectively targets the KRAS G12D mutation, a common oncogenic driver in various cancers. This compound exhibits potent inhibitory activity, making it a valuable tool for studying KRAS-driven tumor biology and developing targeted therapies. Its application in cancer research aids in understanding the molecular mechanisms of KRAS mutations and their role in tumor progression.

Cat. No.

A63708

CAS No.

2508134-76-5

KRAS G12C inhibitor 55

KRAS G12C inhibitor 55 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound effectively disrupts KRAS signaling pathways, leading to inhibited cell proliferation in cancer models. It is primarily utilized in research focused on the development of targeted therapies for tumors harboring KRAS G12C mutations.

Cat. No.

A63709

CAS No.

2762632-78-8

KRAS G12C inhibitor 51

KRAS G12C inhibitor 51 is a selective inhibitor targeting the mutant form of the KRAS protein, specifically the G12C variant. This compound exhibits significant biological activity in suppressing KRAS-driven signaling pathways, making it a valuable tool for cancer research, particularly in studies focused on tumors harboring KRAS G12C mutations. Its application extends to investigating therapeutic strategies and screening for potential drug candidates in KRAS-related malignancies.

Cat. No.

A63710

CAS No.

623935-08-0

Ras modulator-1

Ras Modulator-1 is a selective modulator of the Ras protein, which plays a critical role in cell signaling pathways associated with growth and differentiation. This compound has been shown to influence the activity of Ras, making it a valuable tool for investigating cancer biology and therapeutic interventions targeting Ras-driven malignancies. Research applications include studying signal transduction mechanisms and evaluating potential treatments in oncogenic signaling pathways.

Cat. No.

A63711

CAS No.

1536470-92-4

SML-8-73-1

SML-8-73-1 is a nucleotide-based inhibitor targeting KRASG12C. This compound demonstrates significant efficacy in inhibiting the activity of KRASG12C, making it a valuable tool for research into non-small cell lung cancer (NSCLC). Its selective inhibition allows for the exploration of KRAS-related signaling pathways and contributes to the understanding of cancer progression and potential therapeutic interventions.

Cat. No.

A63714

CAS No.

2319939-24-5

(S)-CCG-1423

(S)-CCG-1423 is a selective inhibitor of Rho signaling, effectively blocking the nuclear import of myocardin-related transcription factor A (MRTF-A). This compound reduces the nuclear accumulation of MRTF-A, leading to improved glucose uptake and enhanced glucose tolerance in insulin-resistant mouse models. (S)-CCG-1423 demonstrates superior inhibitory activity compared to its SR- and R-isomers, making it a valuable tool for research in the fields of cancer and diabetes.

Cat. No.

A63715

CAS No.

2736599-72-5

KRAS G12C inhibitor 22

KRAS G12C inhibitor 22 selectively targets the mutant form of the KRAS protein, specifically the G12C variant. This compound demonstrates potent inhibition of KRAS G12C activity, making it a valuable tool for studying its role in cancer signaling pathways. It is primarily utilized in research focused on developing targeted therapies for KRAS-driven malignancies.

Cat. No.

A63716

CAS No.

2923669-20-7

INCB159020

INCB159020 is an orally active inhibitor targeting the KRAS G12D mutation, exhibiting a SPR value of 2.2 nM. It demonstrates significant antitumor activity, making it a valuable compound for research focused on cancers driven by KRAS G12D alterations. This reagent is primarily utilized in studies aimed at understanding the mechanisms of KRAS-related oncogenesis and evaluating potential therapeutic strategies.

Cat. No.

A63717

CAS No.

2561529-98-2

MRTX849 ethoxypropanoic acid

MRTX849 ethoxypropanoic acid is a targeted protein ligand-linker conjugate designed for the selective degradation of KRAS G12C. This compound incorporates a specific ligand that binds to KRAS G12C and a PROTAC linker, facilitating the synthesis of PROTAC LC-2, an innovative compound known for its ability to degrade endogenous KRAS G12C with IC50 values ranging from 0.25 to 0.76 µM. MRTX849 ethoxypropanoic acid is essential for research applications focused on targeted protein degradation and cancer therapeutics involving KRAS mutations.

Cat. No.

A63718

CAS No.

158446-29-8

Dorrigocin A

Dorrigocin A is an analog of Migrastatin that targets carboxymethyltransferase involved in Ras processing. It has demonstrated the ability to reverse the morphology of Ras-transformed NIH/3T3 cells, highlighting its potential as an anti-cancer agent. Additionally, Dorrigocin A may offer therapeutic insights for the development of anti-arthritis treatments.

Cat. No.

A63720

CAS No.

2642135-72-4

Pan-RAS-IN-7

Pan-RAS-IN-7 is a pan RAS inhibitor that targets the RAS signaling pathway, crucial in cancer biology. This compound exhibits significant anti-tumor activity and is valuable for cancer research applications, particularly in the development of antibody-drug conjugates (ADCs). Its ability to inhibit various RAS isoforms makes it a versatile tool for studying RAS-mediated oncogenic processes.